Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04822337 · ClinicalTrials.gov registry record · Phase 1
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 2
- Study locations
NCT04822337 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 70 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04822337, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and their cancer, and to evaluate the overall response to this study treatment combination.
Conditions Studied
Interventions
- DRUG Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
Study Locations (2)
North Carolina
- Levine Cancer Institute - Charlotte
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-05-19 |
| Est. Completion | 2032-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04822337
The ClinicalTrials.gov registry entry for NCT04822337 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (87% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin is the first listed.
NCT04822337 reports 2 study locations spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04822337 about?
NCT04822337 is a clinical study titled "Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma". This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and their cancer, and t...
What is the current status of trial NCT04822337?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2021-05-19. Estimated completion is 2032-11.
What conditions does trial NCT04822337 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT04822337?
The interventions under investigation include: Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin (DRUG).
Who is sponsoring clinical trial NCT04822337?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04822337 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.